+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating patient satisfaction, effectiveness, and safety of the drug Atezolizumab given by subcutaneous injection in people treated for certain cancers in routine healthcare settings. This observational study includes participants with specific types of lung cancer and hepatocellular carcinoma who receive Atezolizumab according to approved indications without altering their usual treatment plans. Participants are grouped into cohorts based on their diagnosis, including early-stage non-small cell lung cancer NSCLC after surgery and chemotherapy, metastatic NSCLC, extensive-stage small cell lung cancer ES-SCLC, and advanced or unresectable hepatocellular carcinoma HCC. The treatment with Atezolizumab is administered by the participants doctor independently of study participation. Throughout the study, participants report their satisfaction with the subcutaneous therapy using questionnaires at specific treatment cycles, and their quality of life is assessed by standardized tools. Researchers monitor survival outcomes and adverse events for up to approximately 3.5 years. The study captures real-world data on treatment experiences and monitors safety and effectiveness during routine clinical care.

Age: 18Years +All Genders
92 locations
S

Actively Recruiting

Autosomal dominant polycystic kidney disease ADPKD is a condition where kidney cysts progressively form and lead to declining kidney function. Researchers are evaluating whether adding hydrochlorothiazide HCT can improve the effectiveness and tolerability of tolvaptan, the only current treatment for preserving kidney function in ADPKD. This Phase 3 randomized, placebo-controlled trial aims to enroll around 300 adults with ADPKD who are already on a stable dose of tolvaptan. Participants will be randomly assigned to receive either oral hydrochlorothiazide 25 mg once daily or a matching placebo for 156 weeks. The study involves regular visits every 12 weeks, which align with routine care for tolvaptan-treated patients, plus an extra visit or phone call two weeks after starting the study drug. The trial is designed to assess whether co-treatment with HCT can slow kidney function decline and improve quality of life compared to placebo. During the study, participants will undergo kidney function tests, including measurements of estimated glomerular filtration rate eGFR, urine volume, and various blood chemistry tests. Quality of life will be assessed with several questionnaires. Researchers will also monitor V2 receptor antagonist dosing changes, adverse events, and kidney-related outcomes. The total participation time spans about three years, with assessments continuing 12 weeks after treatment ends to evaluate long-term effects.

Age: 18Years - 80YearsAll GendersPhase 3
25 locations
O

Actively Recruiting

Researchers are conducting a national, multicenter observational study called SOGUG-PRINCIS to collect and analyze data on patients with genitourinary cancers treated with recently approved drugs under routine clinical practice in Spain. This study is both retrospective and prospective, aiming to validate real-world effectiveness of these drugs and support future funding decisions. It will serve as a registry where new subprojects will open whenever new drugs receive authorization. The study follows patients who have started treatment with specific drugs funded by the Spanish National Health System, including darolutamide combined with androgen deprivation therapy and docetaxel for hormone-sensitive prostate cancer, adjuvant nivolumab after surgery for urothelial carcinoma, and enfortumab vedotin for urothelial carcinoma. All treatments follow their approved dosing and administration guidelines and standard clinical practice. Participants progress will be monitored through routine data collection to evaluate outcomes such as progression-free survival at 18 months, relapse-free survival at 24 months, and overall survival at 12 months after starting treatment. Data will be gathered from patients treated at participating centers, with follow-up continuing as per routine care. The study does not intervene in treatment decisions, which are made independently before enrollment.

Age: 18Years +All Genders
84 locations
O

Actively Recruiting

This research aims to collect detailed information about patients with lung cancer and other thoracic tumors to better understand the disease and treatment outcomes. It focuses on individualizing treatment based on markers that predict response to chemotherapy and molecular inhibitors. The study addresses challenges such as poor prognosis, variability in diagnosis and treatment, and the need for improved early detection and prevention strategies across Europe and Spain. The study is observational and multicenter, gathering data both retrospectively and prospectively from patients diagnosed and treated by medical professionals including thoracic surgeons and oncologists. It includes multiple groups of patients based on the type of thoracic tumor, such as non-small cell lung cancer, small cell lung cancer, mesothelioma, thymic cancer, and carcinoid cancer. There are no experimental treatments instead, it involves comprehensive data collection on patient characteristics and treatments. Participants provide information from their medical history and treatment records over up to 10 years. Researchers study epidemiological and therapeutic factors related to thoracic tumors by reviewing clinical data. The main outcome is to describe characteristics of these tumors in Spanish patients. The study involves no interventions or medications, focusing on observation and data analysis to inform future care and research.

All AgesAll Genders
79 locations